Skip to main content
BetterLife Pharma logo

BetterLife Pharma — Investor Relations & Filings

Ticker · BETR CSE Professional, scientific and technical activities
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CA Canada
Listing CSE BETR

About BetterLife Pharma

https://abetterlifepharma.com/

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing novel, patient-friendly compounds to treat neuro-psychiatric and neurological disorders, addressing significant unmet mental health needs. The company's core strategy involves revolutionizing brain health by producing non-hallucinogenic medicines. Its lead product candidate is 2-Bromo-LSD (BETR-001), a second-generation lysergic acid diethylamide (LSD) derivative. BETR-001 is designed to mimic the projected therapeutic properties of LSD, acting as a potent neuroplastogen, but without causing psychedelic effects or incurring the high regulatory hurdles associated with Schedule 1 controlled substances. BETR-001 is being developed as a potential therapy for debilitating conditions such as treatment-resistant depression, PTSD, anxiety, and cluster headaches.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2026-04-20 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2026-04-20 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a non-brokered private placement (the issuance of units comprising common shares and warrants for aggregate gross proceeds), detailing pricing, total proceeds, insider participation, and exemptions under MI 61-101. This is an update on a company fundraising / financing activity, which fits the Capital/Financing Update category.
2026-04-18 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a non-brokered private placement. It details the number of units issued, exercise prices of warrants, aggregate proceeds, insider participation exemptions under securities rules, and hold periods. This is clearly a fundraising/capital structure update rather than a full financial report, regulatory filing, or management presentation. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-18 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a company press release announcing the issuance of 600,000 new common shares to an advisor and the extension of convertible debentures’ maturity dates, which are changes to the company’s capital structure. It is not a financial results announcement or an annual/interim report, but a capital/financing update focusing on share issuance and debt instrument extension. Thus it fits the Share Issue/Capital Change category.
2026-04-10 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a corporate news release announcing the issuance of 600,000 common shares to a corporate advisor and the extension of the maturity dates of convertible debentures. This is an announcement of changes to the company’s capital structure (new share issue and debt instrument extension). Accordingly, it best fits the Share Issue/Capital Change category (SHA).
2026-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.